Bellerophon Therapeutics LLC Share Price Nasdaq
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
12:09pm | North American Morning Briefing : Stock Futures -2- | DJ |
04-25 | North American Morning Briefing : More Tech -2- | DJ |
Sales 2021 | - | Sales 2022 | - | Capitalization | 8.59M 0 685M |
---|---|---|---|---|---|
Net income 2021 | -17M - -1.36B | Net income 2022 | -19M - -1.52B | EV / Sales 2021 | - |
Net cash position 2021 | 23.78M 0 1.9B | Net cash position 2022 | 6.72M 0 536M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.66
x | P/E ratio 2022 |
-0.43
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.97% |
Latest transcript on Bellerophon Therapeutics LLC
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 28/01/15 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 28/06/15 |
1st Jan change | Capi. | |
---|---|---|
-1.88% | 104B | |
+6.53% | 97.47B | |
+5.71% | 22.25B | |
-12.62% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.15% | 16.36B | |
+7.03% | 14.39B | |
+36.57% | 12.37B |